Rona Yaeger
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Rona Yaeger as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:54 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07691489 · A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal CancerMemorial Sloan Kettering Cancer Center · not yet recruiting · Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum · principal investigator
- Ph1NCT01791309 · Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal CancerMemorial Sloan Kettering Cancer Center · completed · Metastatic Colorectal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal CancerR01CA288880 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2024 to 2026 · $402,600 awarded in 2026Same name and institution; not confirmed by an ID
- Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment ResponseR21CA292178 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2025 to 2026 · $246,840 awarded in 2026Same name and institution; not confirmed by an ID
- Targeting the Epidermal Growth Factor Receptor (EGFR) to Revert Trastuzumab Deruxtecan Resistance in HER2-low Colorectal Cancer.R01CA296285 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2025 to 2026 · $520,487 awarded in 2026Same name and institution; not confirmed by an ID
- Exploiting the distinct genomics and signaling of colorectal cancers to effectively target ERKR01CA233736 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2019 to 2024 · $237,941 awarded in 2024Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in colorectal cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:54 UTC. The ranking covers the 200 most relevant of 23 PubMed records, and a shared surname and initials can bring in a namesake. All 23 on PubMed
- PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.N Engl J Med · 20221,341 citationsRCR 92.5
- 1,198 citationsRCR 43.0
- Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.J Clin Oncol · 2022830 citationsRCR 71.5
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.Cancer Discov · 2018502 citationsRCR 15.3
- 464 citationsRCR 38.1
- 454 citationsRCR 23.9
- Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial.J Clin Oncol · 2024329 citationsRCR 55.3
- A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.Cancer Discov · 2017203 citationsRCR 5.7
- Nonoperative Management of Mismatch Repair-Deficient Tumors.N Engl J Med · 2025193 citationsRCR 40.4
- 190 citationsRCR 6.4